Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus High-dose Dexamethasone in First-line Adult ITP
NCT05369364Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Phase 2, randomised, open-label trial of zanubrutinib in immune thrombocytopenia (ITP) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Sustained response at 12 months. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05369364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369364.